☰

David T. Miyamoto, M.D., Ph.D.

Affiliations: 
2011- Harvard University, Cambridge, MA, United States 
 2011- Massachusetts General Hospital, Boston, MA 
Area:
Circulating Tumor Cells, Prostate cancer, Bladder cancer, Biomarkers, Microtubules, Actin, Mitosis, Cell cycle
Google:
"David Miyamoto"
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
Timothy J. Mitchison grad student 2004 Harvard
 (Probing the functions of kinesins in mitosis.)
Daniel A. Haber post-doc 2009-2017 Harvard Medical School

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Guo H, Vuille JA, Wittner BS, et al. (2023) DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell
Madueke I, Lee RJ, Miyamoto DT. (2022) Circulating Tumor Cells and Circulating Tumor DNA in Urologic Cancers. The Urologic Clinics of North America. 50: 109-114
Karabacak NM, Zheng Y, Dubash TD, et al. (2022) Differential kinase activity across prostate tumor compartments defines sensitivity to target inhibition. Cancer Research
Miyamoto DT, Lee RJ. (2020) PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer. European Urology
de Jong JJ, Boormans JL, van Rhijn BWG, et al. (2020) Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. European Urology Oncology
Fisher RR, Pleskow HM, Bedingfield K, et al. (2019) Noncanonical Wnt as a prognostic marker in prostate cancer: "You can't always get what you Wnt". Expert Review of Molecular Diagnostics
Batista da Costa J, Gibb EA, Bivalacqua TJ, et al. (2019) Molecular characterization of neuroendocrine-like bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Zheng Y, Comaills V, Burr R, et al. (2019) COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America
Efstathiou JA, Mouw KW, Gibb EA, et al. (2019) Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer. European Urology
Costa JBD, Gibb EA, Bivalacqua TJ, et al. (2019) Molecular characterization of neuroendocrine-like bladder cancer European Urology Supplements. 18
See more...